Supportive care
No publications this month related to supportive care in myeloma
General
Panobinostat Approved for Multiple Myeloma. [No authors listed. Cancer Discov. 2015 Mar 23. [Epub ahead of print]. American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma. Glavey SV et al. Expert Rev Hematol. 2015 Mar 24:1-3. [Epub ahead of print]. Recent advances in multiple myeloma. Kohgo Y et al. Int J Clin Oncol. 2015 Mar 20. [Epub ahead of print]. Patterns of total cost…
Current treatments
Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation. Roy V et al. Blood Cancer J. 2015 Mar 20;5:e294. doi: 10.1038/bcj.2015.23. Phase III trial of bortezomib, cyclophosphamide, dexamethasone (VCD) versus bortezomib, doxorubicin, dexamethasone (PAd) in newly-diagnosed myeloma. Mai EK et al. Leukemia. 2015 Mar 19. doi: 10.1038/leu.2015.80. [Epub…
Complications of myeloma and its treatments
Cytomegalovirus reactivation in patients with multiple myeloma. Hasegawa T et al. Eur J Haematol. 2015 Mar 21. doi: 10.1111/ejh.12551. [Epub ahead of print] Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Gonsalves WI et al. Blood Cancer J. 2015 Mar 20;5:e296. doi: 10.1038/bcj.2015.20. Multiple myeloma presenting with a maxillary lesion as the first sign. Ramaiah KK et…
Diagnostic tests and prognostic indicators
Iterative Decomposition of Water and Fat with Echo Asymmetry and Least-Squares Estimation (IDEAL) Magnetic Resonance Imaging as a Biomarker for Symptomatic Multiple Myeloma. Takasu M et al. PLoS One. 2015 Feb 23;10(2):e0116842. doi: 10.1371/journal.pone.0116842. Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma. Vij R et al. Leuk Lymphoma. 2015 Feb 20:1-12. [Epub ahead…
Supportive care
OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. Holtick U et al. Eur J Haematol. 2015 Feb 23. doi: 10.1111/ejh.12541. [Epub ahead of print]. Use of allogeneic platelet gel in the management of chemotherapy extravasation injuries: a case report. Di Costanzo G et al. Onco…
General
The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence. Hostenkamp G et al. Soc Sci Med. 2015 Feb 7;130C:162-171. doi: 10.1016/j.socscimed.2015.02.003. [Epub ahead of print]. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease. Ashjian E et al. J Oncol Pharm Pract. 2015 Feb 17. pii: 1078155215572036. [Epub ahead of print]. Advance…
Complications of myeloma and its treatments
Management of tumor lysis syndrome in patients with multiple myeloma during bortezomib treatment. Wang L et al. Clin J Oncol Nurs. 2015 Feb 1;19(1):E4-7. doi: 10.1188/15.CJON.E4-E7. Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib. Peng L et al. Support Care Cancer. 2015 Feb 13. [Epub ahead of print]. Renal insufficiency retains adverse prognostic implications despite renal function improvement following…
Current treatments
The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit.
Harrison SJ et al. Am J Hematol. 2015 Feb 4. doi: 10.1002/ajh.23967. [Epub ahead of print].
Supportive care
Plasmapheresis in cast nephropathy: yes or no? Madore F. Curr Opin Nephrol Hypertens. 2015 Jan 14. [Epub ahead of print]. Antimicrobial peptides: an alternative for innovative medicines? da Costa JP et al. Appl Microbiol Biotechnol. 2015 Jan 15. [Epub ahead of print]. Outcomes following surgical intervention for impending and gross instability caused by multiple myeloma in the spinal column. Zadnik PL et al. J…